ArticleFuture neurology2011
Modeling neurological diseases using patient-derived induced pluripotent stem cells.
Article in Future neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- From Biophysics to Biomedical Physics.ACS bio & med chem Au · 2025Review
- Review
- GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy.Molecular therapy. Methods & clinical development · 2022Review
- Biological implications of genetic variations in autism spectrum disorders from genomics studies.Bioscience reports · 2021Review
- Review
- 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling.Molecular neurodegeneration · 2018Review
- A2E-associated cell death and inflammation in retinal pigmented epithelial cells from human induced pluripotent stem cells.Stem cell research · 2018Article
- CRISPR-mediated genome editing and human diseases.Genes & diseases · 2016Review
- Modeling synaptogenesis in schizophrenia and autism using human iPSC derived neurons.Molecular and cellular neurosciences · 2016Review
- Quantification of dopaminergic neuron differentiation and neurotoxicity via a genetic reporter.Scientific reports · 2016Article
- Modeling psychiatric disorders with patient-derived iPSCs.Current opinion in neurobiology · 2016Review
- Spinal muscular atrophy patient-derived motor neurons exhibit hyperexcitability.Scientific reports · 2015Article
- Transdifferentiation of Fibroblasts by Defined Factors.Cellular reprogramming · 2015Review
- Transcripts involved in calcium signaling and telencephalic neuronal fate are altered in induced pluripotent stem cells from bipolar disorder patients.Translational psychiatry · 2014Article
- Direct reprogramming of adult cells: avoiding the pluripotent state.Stem cells and cloning : advances and applications · 2014Review
- Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells.Acta pharmacologica Sinica · 2013Review
- Current status of drug screening and disease modelling in human pluripotent stem cells.BioEssays : news and reviews in molecular, cellular and developmental biology · 2013Review
- Patient-derived stem cells: pathways to drug discovery for brain diseases.Frontiers in cellular neuroscience · 2013Article
- Pluripotent stem cells models for Huntington's disease: prospects and challenges.Journal of genetics and genomics = Yi chuan xue bao · 2012Review
- Application of reprogrammed patient cells to investigate the etiology of neurological and psychiatric disorders.Frontiers in biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Reprogramming of somatic cells to an embryonic-like state has dramatically changed the landscape of stem cell research. Although still in its formative stages, the field of induced pluripotent stem cells (iPSCs) has the potential to advance the study of neurodegenerative and neurodevelopmental disorders at the molecular and cellular levels. The iPSC technology could be employed to establish in vitro experimental model systems for the identification of molecular lesions and to aid in the discovery of therapeutic targets and effective compounds. The derivation of patient-specific iPSCs has also opened up the possibility of generating disease-relevant cells for toxicity screening and for cellular therapy. In this article, we review the recent progress in the use of disease-specific iPSCs for in vitro and in vivo modeling of neurological diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.